A New Serum Macrophage Checkpoint Biomarker for Innate Immunotherapy: Soluble Signal-Regulatory Protein Alpha (sSIRPα)
<b>Background and Aims:</b> The macrophage “don’t eat me” pathway CD47/SIRPα is a target for promising new immunotherapy. We hypothesized that a soluble variant of SIRPα is present in the blood and may function as a biomarker. <b>Methods:</b> Monocyte derived macrophages (MDM...
Main Authors: | Yoanna V. Vladimirova, Marie K. Mølmer, Kristian W. Antonsen, Niels Møller, Nikolaj Rittig, Marlene C. Nielsen, Holger J. Møller |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-07-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-273X/12/7/937 |
Similar Items
-
Research Progress of CD47-SIRPα Signaling Axis as An Innate Immune Checkpoint in Cancer
by: ZHA Li, et al.
Published: (2018-08-01) -
Role of CD47-SIRPα Checkpoint in Nanomedicine-Based Anti-Cancer Treatment
by: Haiqin Liao, et al.
Published: (2022-04-01) -
Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis
by: Jinyang Hu, et al.
Published: (2020-11-01) -
Targeting the CD47-SIRPα Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils
by: Leonie M. Behrens, et al.
Published: (2022-07-01) -
Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα–CD47 innate immune checkpoint
by: Erik Voets, et al.
Published: (2019-12-01)